Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease

Arwen Stikvoort1, Yang Chen2, Emelie Rådestad3

  • 1Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.

Insights

Researchers identified immune cell biomarkers for chronic graft-versus-host disease (cGVHD) severity using advanced cytometry techniques. These findings could lead to better diagnostic tools and treatments for this debilitating complication after stem cell transplants.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation, significantly impacting patient morbidity and mortality.
  • Current diagnostic and classification methods for cGVHD often rely on invasive tissue biopsies.
  • There is a critical need for non-invasive blood-based biomarkers to aid in cGVHD diagnosis, severity assessment, and treatment development.

Purpose of the Study:

  • To systematically profile immune cell populations in patients with varying grades of cGVHD.
  • To identify novel immune cell subpopulations that can serve as diagnostic and prognostic markers for cGVHD.
  • To explore the potential of mass and flow cytometry for cGVHD biomarker discovery and validation.

Main Methods:

  • Utilized mass cytometry, flow cytometry, enzyme-linked immunosorbent assay, and multiplex assays to analyze immune cells from 68 cGVHD patients.
  • Systematically profiled T-cell, B-cell, and NK-cell lineages to identify disease-specific signatures.
  • Correlated immune cell profiles with clinical data on cGVHD severity.

Main Results:

  • Identified distinct immune cell subpopulations across T, B, and NK lineages associated with cGVHD presence and severity.
  • Observed lower mucosal-associated T-cell frequencies and higher CD38 expression on T cells in severe cGVHD.
  • Detected varying frequencies of activated B cells depending on cGVHD severity, suggesting complex immune dysregulation.
  • Found increased B-cell activating factor/B cell ratio in mild cGVHD, with no significant changes in other soluble markers.

Conclusions:

  • Immune cell subpopulations identified through comprehensive profiling hold promise as diagnostic and therapeutic targets for cGVHD.
  • Mass cytometry findings may be validated using smaller, clinically applicable flow cytometry panels.
  • Interdependencies among perturbed immune cell subpopulations likely contribute to cGVHD pathogenesis, highlighting avenues for future research and clinical intervention.